Dave Fornell, DAIC Editor

Dave Fornell, Editor DAIC

Blog | Dave Fornell, DAIC Editor | April 08, 2014

Key News and Technology at ACC.14

By Dave Fornell

The biggest news item from the American College of Cardiology (ACC) 63rd Annual Scientific Session was that a transcatheter aortic valve had 26 percent better survival in high-risk patients than surgical valve replacement. This is a big deal, as it shows the promise of transcatheter valve technology to eventually replace open-heart surgical procedures is not a theory out in left field. What is more impressive is the fact that the operators were given three patients to learn how to use the CoreValve device before their fourth and subsequent patients counted in the trial. Despite the relative inexperience with the device and procedure compared to cardiac surgeons, who in most cases have been performing valve replacements for a decade or longer, the fact that the new device outperformed surgery is very impressive. Read more on the trial or watch a video interview with one of the lead investigators.

The major disappointment at ACC.14 was the presentation of the SYMPLICITY HTN-3 renal denervation U.S. pivotal trial. The device used failed to reduce blood pressure a statistically significant amount over a sham procedure, calling into question the future of denervation technology. This session was packed solid with thousands of attendees, who wanted to hear the details and what the future might be for this technology. Read more on the trial or watch a video interview with one of the investigators.

A key late-breaking presentation for cardiac imaging was a combination of five trials that show coronary artery calcium scoring provides an early indication of a patient’s long-term risk for heart disease. Read more on the trial.

A key presentation in electrophysiology was the long-term results from the MADIT-CRT trial, which showed greatly improved outcomes and survival in heart failure patients with left bundle branch block. Read more on the trial.

I walked the exposition show floor and found several new, innovative technologies and on display. I also found some technologies that highlight trends in cardiology, including examples of how to achieve patient engagement and enterprise imaging. Watch the video “DAIC Editor’s Choice for Most Innovative New Technology.”

Related Content

Diabetes Drug May Reverse Heart Failure
News | Heart Failure | April 19, 2019
Researchers at the Icahn School of Medicine at Mount Sinai have demonstrated that the recently developed antidiabetic...
Diabetes Drug Effective Against Heart Failure in Wide Spectrum of Patients
News | Heart Failure | March 29, 2019
The cardiovascular benefits of the diabetes drug dapagliflozin extend across a wide spectrum of patients and are...
New data from a four-week extension of the landmark PIONEER-HF Trial showed the drug sacubitril/valsartan (Entresto) continued to deliver reductions in the heart failure biomarker N-terminal pro–B-type natriuretic peptide (NT-proBNP), an established biomarker for heart failure severity and prognosis.[1] The data was presented as a late-breaker at the American College of Cardiology (ACC) 2019 Annual Scientific Session in March.
News | Heart Failure | March 27, 2019
March 27, 2019 —New data from a four-week extension of the landmark PIONEER-HF Trial showed the drug sacubitril/valsa
Toilet Seat Detects Congestive Heart Failure

Nicholas Conn, a postdoctoral fellow at RIT and founder and CEO of Heart Health Intelligence, is part of the university team that has developed a toilet-seat based cardiovascular monitoring system. Image courtesy of A. Sue Weisler/RIT.

News | Heart Failure | March 26, 2019
March 26, 2019 — A toilet seat-based ...
FDA Approves Optimizer Smart System for Heart Failure Patients offers cardiac contractility modulation.
Technology | Heart Failure | March 21, 2019
The U.S. Food and Drug Administration (FDA) approved Impulse Dynamics’ Optimizer Smart system for treating patients...
William T. Abraham, M.D., Joins V-Wave as Chief Medical Officer

William T. Abraham, M.D., in an interview with DAIC Editor Dave Fornell at TCT 2016.

News | Heart Failure | March 12, 2019
V-Wave Ltd. announced that renowned heart failure cardiologist William T. Abraham, M.D., is joining V-Wave as chief...
EMPRISE Study Shows Empagliflozin Reduces Heart Failure Hospitalization with new data presented at AHA 2018. #AHA18 #AHA2018
News | Heart Failure | November 07, 2018
November 6, 2018 – Initial results from the real-world EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) s
Overlay Init